Biologic drug for eosinophilic esophagitis lowers childhood asthma risk
Young children treated for eosinophilic esophagitis (EoE) with dupilumab (a biologic medication) were less likely to develop asthma in the future compared with children who received a different treatment.
Read original article on The Medical News →Related news
-
Scientists identify protein driving age-related organ damage
United Kingdom
-
College student mental health improves, but significant needs remain
United Kingdom
-
Biologic drug offers promising protection against alpha-gal syndrome
United Kingdom
-
Stocking epinephrine in schools protects students and eases family financial burdens
United Kingdom
-
Language barriers delay early peanut introduction for many infants
United Kingdom
-
Study reveals frequent insurance denials for pediatric biologic allergy treatments
United Kingdom
-
Blood thinner could offer a new way to treat osteoarthritis
United Kingdom
-
Three decision-making styles emerge when people weigh probability words against numbers, researchers report
United Kingdom